The Hang Seng Index may undergo a "major transformation" in December: Pop Mart and Kuaishou are expected to be included, bringing the number of constituent stocks back to 100.

Currently, the Hang Seng Index in Hong Kong includes 82 stocks, with the ultimate goal of expanding the number of constituent stocks to 100. Analysis suggests that the medical care industry is still the least represented industry in the Hang Seng Index, while consumer staples, discretionary items, real estate, and construction may receive higher weights in the review in the fourth quarter of this year.

wallstreetcn10:21

The trend of mergers and acquisitions blowing towards the pharmaceutical track, experts remind to pay attention to these risks.

Since the release of the "Six Guidelines for Mergers and Acquisitions", mergers and acquisitions in the pharmaceutical field have begun to accelerate. As of November 20, at least 20 companies have first disclosed their relevant plans for mergers and reorganizations. Experts remind that the pharmaceutical field has a high level of specialization and also requires careful consideration of risk factors such as professional fit prior to mergers and reorganizations.

cls.cnNov 21 10:41

Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation

①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.

cls.cnNov 19 21:17

On a single day, there was a massive purchase of 13.5 billion Hong Kong dollars! Southern capital aggressively rushes to invest, when will the Hong Kong stock market welcome investment opportunities?

Southbound funds are accelerating their purchases of Hong Kong stocks.

Brokerage ChinaNov 19 12:15

The registration for the 13-valent combined pneumococcal vaccine has been officially accepted, and it has obtained a pharmaceutical production license.

China Finance OnlineNov 15 13:34

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

① During the earnings conference, fosun pharma stated that the company's performance improved year-on-year in Q3 due to factors such as the continuous increase in innovative drug volume. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the rapid上市 and sales of injectable type A botulinum toxin within china. ③ The privatization process of henlius and the accessibility of CAR-T products are also receiving significant attention.

cls.cnNov 13 21:52